213 related articles for article (PubMed ID: 18799100)
1. Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy.
Walsh CA; Fearon U; FitzGerald O; Veale DJ; Bresnihan B
Clin Exp Rheumatol; 2008; 26(4):656-8. PubMed ID: 18799100
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
[TBL] [Abstract][Full Text] [Related]
3. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results.
Kavanaugh A; Rosengren S; Lee SJ; Hammaker D; Firestein GS; Kalunian K; Wei N; Boyle DL
Ann Rheum Dis; 2008 Mar; 67(3):402-8. PubMed ID: 17644541
[TBL] [Abstract][Full Text] [Related]
4. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.
Teng YK; Levarht EW; Toes RE; Huizinga TW; van Laar JM
Ann Rheum Dis; 2009 Jun; 68(6):1011-6. PubMed ID: 18647852
[TBL] [Abstract][Full Text] [Related]
5. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis.
Vos K; Thurlings RM; Wijbrandts CA; van Schaardenburg D; Gerlag DM; Tak PP
Arthritis Rheum; 2007 Mar; 56(3):772-8. PubMed ID: 17328049
[TBL] [Abstract][Full Text] [Related]
6. CD20 antigen imaging with ¹²⁴I-rituximab PET/CT in patients with rheumatoid arthritis.
Tran L; Huitema AD; van Rijswijk MH; Dinant HJ; Baars JW; Beijnen JH; Vogel WV
Hum Antibodies; 2011; 20(1-2):29-35. PubMed ID: 21558621
[TBL] [Abstract][Full Text] [Related]
7. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response.
Thurlings RM; Vos K; Wijbrandts CA; Zwinderman AH; Gerlag DM; Tak PP
Ann Rheum Dis; 2008 Jul; 67(7):917-25. PubMed ID: 17965121
[TBL] [Abstract][Full Text] [Related]
8. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].
Tanaka Y
Yakugaku Zasshi; 2009 Jun; 129(6):675-9. PubMed ID: 19483410
[TBL] [Abstract][Full Text] [Related]
9. Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis.
Hainsworth JD
Arthritis Res Ther; 2003; 5 Suppl 4(Suppl 4):S12-6. PubMed ID: 15180892
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.
Roll P; Dörner T; Tony HP
Arthritis Rheum; 2008 Jun; 58(6):1566-75. PubMed ID: 18512772
[TBL] [Abstract][Full Text] [Related]
11. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
Tanaka Y
Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614
[No Abstract] [Full Text] [Related]
12. B lymphocyte depletion in rheumatoid arthritis: targeting of CD20.
Edwards JC; Leandro MJ; Cambridge G
Curr Dir Autoimmun; 2005; 8():175-92. PubMed ID: 15564721
[TBL] [Abstract][Full Text] [Related]
13. Improvement of refractory rheumatoid arthritis after depletion of B cells.
Kneitz C; Wilhelm M; Tony HP
Scand J Rheumatol; 2004; 33(2):82-6. PubMed ID: 15163108
[TBL] [Abstract][Full Text] [Related]
14. Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis.
Thurlings RM; Teng O; Vos K; Gerlag DM; Aarden L; Stapel SO; van Laar JM; Tak PP; Wolbink GJ
Ann Rheum Dis; 2010 Feb; 69(2):409-12. PubMed ID: 19596693
[TBL] [Abstract][Full Text] [Related]
15. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.
Rehnberg M; Amu S; Tarkowski A; Bokarewa MI; Brisslert M
Arthritis Res Ther; 2009; 11(4):R123. PubMed ID: 19686595
[TBL] [Abstract][Full Text] [Related]
16. Synovial infiltration with CD79a-positive B cells, but not other B cell lineage markers, correlates with joint destruction in rheumatoid arthritis.
Mo YQ; Dai L; Zheng DH; Zhu LJ; Wei XN; Pessler F; Shen J; Zhang BY
J Rheumatol; 2011 Nov; 38(11):2301-8. PubMed ID: 22002013
[TBL] [Abstract][Full Text] [Related]
17. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.
Bingham CO; Looney RJ; Deodhar A; Halsey N; Greenwald M; Codding C; Trzaskoma B; Martin F; Agarwal S; Kelman A
Arthritis Rheum; 2010 Jan; 62(1):64-74. PubMed ID: 20039397
[TBL] [Abstract][Full Text] [Related]
18. Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor.
Ernestam S; af Klint E; Catrina AI; Sundberg E; Engström M; Klareskog L; Ulfgren AK
Arthritis Res Ther; 2006; 8(1):R18. PubMed ID: 16507118
[TBL] [Abstract][Full Text] [Related]
19. Synovium CD20 expression is a potential new predictor of bone erosion progression in very-early arthritis treated by sequential DMARDs monotherapy -- a pilot study from the VErA cohort.
Lanfant-Weybel K; Michot C; Daveau R; Milliez PY; Auquit-Auckbur I; Fardellone P; Brazier M; Mejjad O; Daragon A; Krzanowska K; Jouen F; Tron F; Le Loarer F; Le Loët X; Vittecoq O
Joint Bone Spine; 2012 Dec; 79(6):574-80. PubMed ID: 22459417
[TBL] [Abstract][Full Text] [Related]
20. New immunomodulators in the treatment of Graves' ophthalmopathy.
Salvi M; Vannucchi G; Campi I; Currò N; Beck-Peccoz P
Ann Endocrinol (Paris); 2008 Apr; 69(2):153-6. PubMed ID: 18417090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
